Comprehensive solutions for implementing risk-sharing models.
Confidential price agreements have become more widespread with regard to hospital medicines, while decisions on conditional reimbursement are becoming more established in the price and reimbursement processes of outpatient medicines.
Confidential agreements can be risk-sharing agreements (for example, pay for performance, conditional treatment continuation, or other contracts that reward the patient for the benefit of the treatment) or a method for sharing and managing uncertainty about the cost and effectiveness of medicines to the satisfaction of both parties. This will eventually make the medicine available to those patients who will benefit from it.
”Risk sharing agreements aim to solve the classic pharmaceutical sales dilemma of who bears the risk of effectiveness and cost effectiveness related to the purchasing and using of medicines.”
“We at Medaffcon execute risk-sharing agreements between the parties, ensuring that the agreements are operational and mutually beneficial. ”
Are you employed in the pharmaceutical industry and seeking insights into your product's position within the Finnish market? Then Patient Dynamics is the ideal tool for you. Developed by Medaffcon, Patient Dynamics caters to the needs of pharmaceutical companies by providing precise information for sales and marketing decision-making.
“Renewable drug therapy challenges the current complex drug evaluation system,” states Lauri Pelkonen, a leading expert at the Ministry of Social Affairs and Health (STM). For this reason, the evaluation activity is being reformed to better respond to changes in the operating environment.
Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
Principal Consultant
Market Access Lead
MSc (Economics)
+358 40 139 4001
jarmo.hahl@medaffcon.fi
Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.
Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment.
“From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.